
When elephant moms need help, nannies step in
Elephant caregivers play an important role in their society by comforting and teaching babies when mom is occupied. Allomothers, aka "nannies," play an important role in elephant society by comforting and teaching babies while giving mom a hand. Photograph By David Chancellor, Nat Geo Image Collection
In December 2023, a 10-year-old African elephant disappeared from her herd in Kenya's Samburu National Reserve. When she returned a month later, she was accompanied by two unrelated females, thought to be about 10 and 15 years old; the younger one had a newborn calf in tow.
What happened next was remarkable, according to Giacomo D'Ammando, research manager for the Kenya-based conservation organization Save the Elephants.
'[The recently returned elephant] had stepped into a caregiver role, helping the inexperienced young mother raise her calf, like a nanny,' D'Ammando says.
While an exceptional story, allomothers—female elephants that help take care of calves that are not their own—have always been around. They play an important role in elephant society by comforting and teaching babies while giving mom a hand.
'They're essentially nannies and they're all over elephant society,' says Shifra Goldenberg, a population sustainability scientist for the San Diego Zoo Wildlife Alliance, who has studied wild elephants in Kenya.
Sometimes older females like grandmothers and aunts fill this role, 'but more commonly, you get this sort of younger age set…who are really attracted to babies, really want to spend time with them and take care of them, and it provides quite a lot of benefits,' she says. Most nannies are less than 15 years old and have never given birth, D'Ammando notes. An elephant matriarch is followed by calves. Photograph By Michael Nichols, Nat Geo Image Collection
Younger allomothers get vital parenting experience as they interact with their adopted calves, Goldenberg explains. Plus, moms get extra eyes on their young one. Since elephants tend to spread out to search for food, 'that helps to have more legs and trunks surrounding your baby,' she adds.
According to D'Ammando, elephant nannies spend a lot of time greeting and touching the baby.
They also comfort distressed calves, often 'touching them all over' with their trunk, according to Goldenberg. D'Ammando says nannies step in to assist in a variety of stressful situations—for instance, if a very young calf falls and cannot walk properly, or if they get stuck in the mud or panic after being separated from their mother.
In high-stress situations, all of the group's females will engage in a group defense, D'Ammando adds. A juvenile elephant plays in a river in Samburu National Park in Northern Kenya.
Photograph By Michale Nichols, Nat Geo Image Collection Two African elephant calves play near a grazing adult elephant.
Photograph By Beverly Joubert, Nat Geo Image Collection A young elephant raises its trunk.
Photograph By Beverly Joubert, Nat Geo Image collection A newborn elephant sleeps in the shade of its mother. Photograph By Michael Nichols, Nat Geo Image Collection
For example, in April, a viral video showed a 5.2-magnitude earthquake at the San Diego Zoo Safari Park in Escondido, California. Three of the park's older female elephants scrambled to form a protective circle around two 6-year-old calves. The actions in this video are a great example of herd dynamics in general, Mindy Albright, the facility's curator of mammals, says.
'Survival strategy is key, right?' she says. 'And so anytime there's any kind of signs of danger, you'll see the herd congregate together and often creating these alert circles where the calves are in the center so that they can be more protected.'
However, Goldenberg says that the 'nanny' elephant's allomothering instincts also came out during the quake. When one of the young elephants first remained on the outside of the circle, his nanny repeatedly tapped him on the back and face as if to encourage him back in.
According to Goldenberg, the relationship between nanny and baby includes a lot of play, which helps calves build confidence to eventually become independent from mom, a years-long process that's different for each elephant, though many are nutritionally independent around 4 years of age. Females ultimately stay with their natal group, while males gradually disperse around age 14.
Elephants also participate in 'allosuckling,' with calves nursing from young females for comfort rather than nutrition. A female elephant cares for two calves orphaned by the deaths of their mothers. Photograph By Michael Nichols, Nat Geo Image Collection
'The allomothers will often sample trying to let the calf nurse from them even though they're not necessarily lactating,' Albright says of the Safari Park's herd. 'So, you see them practice. They'll even use their trunk to try to guide them to their nipple, kind of trying to share with them, 'I can comfort you too, and I'm a resource for that.''
Staff at the Safari Park have also witnessed impromptu sleepovers when tired calves wander over to the allomothers while their mom is foraging.
'They'll go cuddle with them and sleep in these big giant piles of juveniles all taking care of the babies while the moms can still go and forage throughout the night,' Albright says. 'They're really cute.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Dust from Sahara brings hazy skies to East Texas
TYLER, Texas (KETK) — Each year, large plumes of dust from the Sahara in Africa make their way across the Atlantic Ocean and sometimes find their way into the United States, including right here in East Texas. The technical name for this phenomenon is the Saharan air layer. What is a severe weather watch vs warning? These large masses of dust consist of fine particles from the deserts of the northern areas of the African continent, as well as extremely dry air. When the dust makes its way into our area, skies have a hazy tint and sunsets tend to be more vibrant. When the dust plumes are especially potent, you may even notice a thin layer of fine dust on your vehicle or other outdoor objects. Air quality can be negatively affected by Saharan dust, leading to congestion and respiratory issues, particularly in vulnerable populations. Because the air associated with these dust plumes is so dry, the Saharan air layer can suppress the development of tropical cyclones in the Atlantic Ocean. Thicker dust plumes can even cause sea surface temperatures to drop due to the blockage of solar radiation. Tropical systems need plenty of moisture and warm sea surface temperatures to develop, so this combination is a substantial hinderance in tropical development. More dust is expected to move into the region over the coming days. Keep up with all of the latest information on East Texas air quality on KETK News. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
42 minutes ago
- Yahoo
Sanofi to acquire Blueprint for up to $9.5B
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint's research revolves around an enzyme made by a gene called KIT. This 'tyrosine kinase' enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases. Blueprint already has one medicine approved by the Food and Drug Administration, Ayvakit, and is working on a handful of others, two of which are in human testing. The FDA first approved Ayvakit in early 2020 for a rare kind of hard-to-treat gastrointestinal tumor, and specifically for the small subset of adults who have these tumors and certain mutations. Since then, the agency cleared the medicine as a treatment for both the less and more aggressive forms of 'systemic mastocytosis,' an uncommon disorder where a kind of white blood cell known as a mast cell builds up in the bone marrow, digestive tract, skin and other organs. The accumulation can lead to severe inflammation and organ damage. Last year, Blueprint posted $479 million in net product revenue from Ayvakit. The company used to have another marketed cancer drug, Gavreto, which it was co-developing and commercializing with Roche. But Roche ultimately backed away from that alliance, leading Blueprint to sell away rights to Rigel Pharmaceuticals in early 2024. In a statement announcing the deal, Sanofi highlighted the recent trajectory in Ayvakit sales. They were up more than 60%, for example, between the first quarter of 2024 and the same three-month period this year. Blueprint recorded a $67 million net loss in 2024, compared to a more than half-a-billion-dollar net loss in each of the previous two years. The proposed acquisition 'represents a strategic step forward in our rare and immunology portfolios,' Sanofi CEO Paul Hudson said in the Monday statement. 'It enhances our pipeline and accelerates our transformation into the world's leading immunology company.' Hudson added that his company maintains a 'sizeable capacity for further acquisitions.' After being an active dealmaker over the past few years, the French pharmaceutical giant still had close to 8 billion euros in cash and cash equivalents at the end of March. Sanofi bought the diabetes drug developer Provention Bio for almost $3 billion in 2023 and the rare disease-focused Inhibrix for $2.2 billion in 2024. And just last month, it agreed to spend $470 million on Vigil Neuroscience, a Massachusetts-based biotechnology company touting an Alzheimer's disease drug that just finished an early-stage human study. Similar to its Vigil proposal, Sanofi is offering Blueprint investors a so-called contingent value right that could be worth up to $6 per Blueprint share, provided one of the biotech's experimental drugs, 'BLU-808,' hits certain development and regulatory goals. BLU-808 is in mid-stage testing as a possible treatment for chronic hives and an allergy-related condition that causes runny eyes and a congested nose. Blueprint also believes the drug could be useful in treating allergic asthma and 'mast cell activation syndrome.' Another Blueprint drug, elenestinib, is further along, having advanced to a late-stage study for the slower-moving form of systemic mastocytosis. Sanofi's upfront payment of $9.1 billion values Blueprint shares at $129 apiece, reflecting a premium of about 27% from the biotech's closing stock price on Friday. The transaction is expected to close sometime between July and the end of September, according to Sanofi. Andrew Berens, an analyst at the investment firm Leerink Partners, wrote in a note to clients how his team expected Blueprint to land on the 'strategic radar of large pharma' given Ayvakit is on the path to $1 billion or more in annual sales and the company recently raised its financial guidance for this year. However, the deal came sooner than anticipated, ahead of a key data readout for a rival drug from Cogent Biosciences. Cogent's bezuclastinib is also being evaluated as a treatment for systemic mastocytosis, with results set to arrive in the next couple months. Regardless of how strong or weak those results will be, Berens believes they'd serve as a tailwind for Blueprint 'by removing a key overhang and allowing a strategic acquirer to structure a deal based on assumptions about ... market dynamics.' As such, Cogent's data could have propped up Blueprint's share price, 'which may have been an impetus for Sanofi to do the deal now,' Berens posited. Even so, the analyst still sees Sanofi's bid as a positive for Blueprint and this field of research. Cogent shares were down by about 2% late Monday morning. Recommended Reading Blueprint wins key FDA approval for rare disease drug Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Clairity receives FDA OK for breast cancer risk prediction tool
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The Food and Drug Administration has authorized the first artificial intelligence tool to predict patients' five-year breast cancer risk from a routine mammogram. Boston-based startup Clairity developed the tool, called Clairity Breast. The company plans to launch the risk assessment feature by the end of the year, according to a Monday announcement. 'We're doing something radically different than what I've done my whole career in the area of computer-aided detection and diagnosis of breast cancer,' Connie Lehman, founder of Clairity and a diagnostic radiologist at Mass General Brigham, said in an interview. AI has been used to detect breast cancer for decades; the first computer-aided detection system for breast cancer was approved in 1998, Lehman said. However, most of these tools are used to detect cancer, not predict future risk. 'What we're doing here is doing something humans can't do,' Lehman said. 'It's extracting subtle cues in the mammogram that the human eye can't see, the human brain can't process.' About 2.3 million new cases of breast cancer were diagnosed worldwide in 2022, according to the latest data from the World Health Organization. Current risk models factor in age and family history, but most people diagnosed have no family history. Lehman, who has focused most of her career on better ways to detect breast cancer early, expects the new approach will 'expand the net out to more women who truly are at high risk, and until now we haven't been able to identify.' Clairity Breast was developed using Hologic's 2D screening mammography systems. It would be used as part of a patient's routine mammogram. The company was careful to train its AI models on a diverse group of patients, Lehman said, as historically, breast cancer risk prediction models were built on data from predominantly white women. Clairity plans to launch the predictive tool starting with select centers and expanding access later this year, Lehman said. The company last year hired Jeffrey Luber as CEO to help lead the market launch. Luber is the former CEO of testing firms Binx Health and Exact Sciences. Clairity received a $1 million investment from the Breast Cancer Research Foundation in January. Recommended Reading Nvidia's David Niewolny on the future of AI in medical devices